European Patent Office

T 0571/10 vom 03.06.2014

Europäischer Rechtsprechungsidentifikator
ECLI:EP:BA:2014:T057110.20140603
Datum der Entscheidung
3. Juni 2014
Aktenzeichen
T 0571/10
Antrag auf Überprüfung von
-
Anmeldenummer
08165575.5
Verfahrenssprache
Englisch
Verteilung
An die Kammervorsitzenden und -mitglieder verteilt (B)
Amtsblattfassungen
Keine AB-Links gefunden
Weitere Entscheidungen für diese Akte
-
Zusammenfassungen für diese Entscheidung
-
Bezeichnung der Anmeldung
Pharmaceutical compositions comprising a HMG COA reductase inhibitor
Name des Antragstellers
AstraZeneca AB
Name des Einsprechenden
-
Kammer
3.3.07
Leitsatz
-
Schlagwörter
Late-filed request - justification for late filing (yes)
Divisional application - added subject-matter (no)
Claims - essential features
Amendments - added subject-matter (no)
Priority - "OR"-claims using a generic term or formula
Priority - partial priority (yes)
Novelty - (yes)
Inventive step - (yes)
Orientierungssatz
In a case in which a single priority is claimed for a given application and a number of features of a claim of said application are generalisations of specific features disclosed in the priority document, a partial priority is to be acknowledged, as long as it is possible to conceptually identify, by a comparison of the claimed subject-matter with the disclosure of the priority document, a limited number of clearly defined alternative subject-matters, including among the alternatives the specific embodiments which are directly and unambiguously derivable from the priority document. In order for this condition to be met, it is not necessary that the clearly defined alternative subject-matters are spelt out as such in the application, nor that the word "or" actually occurs (see point 4.5.12).
This condition extends to the case of multiple priorities. In that case, a comparison with the disclosure of each of the priority documents is necessary and for each of the clearly defined alternative subject-matters the earliest priority from which the alternative subject-matter is directly and unambiguously derivable is acknowledged (see point 4.5.13).
Zitierende Akten
G 0001/15T 0557/13

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the department of first instance with the order to grant a patent on the basis of claims 1 to 12 filed during the oral proceedings before the Board and a description yet to be adapted thereto.